Cited by 284Prostate Cancer Treatment and ResearchChromatin Remodeling and CancerCancer Genomics and Diagnostics

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer

Open access

Parolia, Abhijit, Cieslik, Marcin, Chu, Shih-Chun, Xiao, Lanbo, Ouchi, Takahiro, Zhang, Yuping, Wang, Xiaoju, Vats, Pankaj, Cao, Xuhong, Pitchiaya, Sethuramasundaram, Su, Fengyun, Wang, Rui, Feng, Felix Y., Wu, Yi-Mi, Lonigro, Robert J., Robinson, Dan R., Chinnaiyan, Arul M.·2019·Nature

DOI 10.1038/s41586-019-1347-4PMC PMC6661908

Open this paper in CoChat — free account

Abstract

Abtract Forkhead box A1 (FOXA1) is a pioneer transcription factor that is essential for the normal development of several endoderm-derived organs, including the prostate gland 1,2. FOXA1 is frequently mutated in hormone-receptor-driven prostate, breast, bladder and salivary-gland tumours 3-8. However, it is unclear how FOXA1 alterations affect the development of cancer, and FOXA1 has previously been ascribed both tumour-suppressive 9-11 and oncogenic 12-14 roles. Here we assemble an aggregate cohort of 1,546 prostate cancers and show that FOXA1 alterations fall into three structural classes that diverge in clinical incidence and genetic co-alteration profiles, with a collective prevalence of 35%. Class-1 activating mutations originate in early prostate cancer without alterations in ETS or SPOP, selectively recur within the wing-2 region of the DNA-binding forkhead domain, enable enhanced chromatin mobility and binding frequency, and strongly transactivate a luminal androgen-receptor program of prostate oncogenesis. By contrast, class-2 activating mutations are acquired in metastatic prostate cancers, truncate the C-terminal domain of FOXA1, enable dominant chromatin binding by increasing DNA affinity and-through TLE3 inactivation-promote metastasis driven by the WNT pathway. Finally, class-3 genomic rearrangements are enriched in metastatic prostate cancers, consist of duplications and translocations within the FOXA1 locus, and structurally reposition a conserved regulatory element-herein denoted FOXA1 mastermind (FOXMIND)-to drive overexpression of FOXA1 or other oncogenes. Our study reaffirms the central role of FOXA1 in mediating oncogenesis driven by the androgen receptor, and provides mechanistic insights into how the classes of FOXA1 alteration promote the initiation and/or metastatic progression of prostate cancer. These results have direct implications for understanding the pathobiology of other hormone-receptor-driven cancers and rationalize the co-targeting of FOXA1 activity in therapeutic strategies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1347-4

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

<tt>edgeR</tt> : a Bioconductor package for differential expression analysis of digital gene expression data
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
MEME SUITE: tools for motif discovery and searching
Bailey, T. L., Boden, M., Buske, F. A., Frith, M., Grant, C. E., Clementi, L., Ren, J., Li, W. W., & Noble, W. S. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp335 · Cited by 10,648
deepTools2: a next generation web server for deep-sequencing data analysis
Ramírez, F., Ryan, D. P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A. S., Heyne, S., Dündar, F., & Manke, T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw257 · Cited by 8,096
Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r29 · Cited by 6,155

Show all 60 references

Research works printed but not linked: 1

Smyth, G. K., McCarthy, D. J. & Smyth, G. K. in Bioinformatics and Computational Biology Solutions Using R and Bioconductor (eds Dudoit, S. & Carey, V. J.) 397–420 (Springer, New York, 2005).

Sorted by citations

Items 201–284 of 284

Molecular subtypes of metastatic prostate cancer: from pathophysiology to diagnosis
Dsouza, J. M., Sayar, E., Schweizer, M. T., Harmon, S. A., Morrissey, C. M., Beltran, H., Nelson, P. S., Liang Cheng, C., Ding, C. C., & Haffner, M. C. (2025) · Histopathology · doi:10.1111/his.70033 · Cited by 4
Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer
Tam, K. J., Liu, L., Hsing, M., Dalal, K., Thaper, D., McConeghy, B. J., Yenki, P., Bhasin, S., Peacock, J. W., Wang, Y. Z., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-57854-w · Cited by 4
Cis -regulatory Element Hijacking by Structural Variants Overshadows Higher-Order Topological Changes in Prostate CancerPreprint
Hawley, J. R., Zhou, S., Arlidge, C., Grillo, G., Kron, K., Hugh-White, R., van der Kwast, T., Fraser, M. E., Boutros, P. C., Bristow, R. G., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.05.425333 · Cited by 4
Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance
Gao, S., Patten, N. D., & Cai, C. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.05.003 · Cited by 4
FOXA1 mutations co-opt nascent transcription factor networks in partnership with androgen receptor to enhance prostate tumorigenicity
Ladewig, E., Nazir, A., Park, T., Fan, V. B., Cao, Z., Hawk, J., Kelly, L., Tjian, R., Leslie, C. S., & Sawyers, C. L. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.116950 · Cited by 3
Genomic landscape and precision therapy in prostate cancer: current status and future directions
Ligon, J. A., Anand, S., Singh, S., Siddiqui, J. A., Henegan, J. C., & Singh, A. P. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01368-3 · Cited by 3
Systematic interrogation of mutation groupings reveals divergent downstream expression programs within key cancer genes
Grzadkowski, M. R., Holly, H. D., Somers, J., & Demir, E. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04147-y · Cited by 2
Usage of the National Cancer Institute Cancer Research Data Commons by Researchers: A Scoping Review of the Literature
Chen, Z., Kim, E., Davidsen, T. M., & Barnholtz‐Sloan, J. S. (2024) · JCO Clinical Cancer Informatics · doi:10.1200/cci.24.00116 · Cited by 3
Rise of the Chromodomain Helicase DNA‐Binding (CHD) Chromatin Remodelling Machines
Alendar, A. (2023) · Wiley eBooks · doi:10.1002/9780470015902.a0029448 · Cited by 3
Integrative analysis of molecular mechanisms in prostate cancer via single-cell RNA sequencing and weighted gene co-expression network analysis
Zhai, J. H., Wang, Y., Zhang, Y., Zhu, W., Xu, X., Peng, Y., & Ding, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-15682-6 · Cited by 2
Self-citation
Chromatin Regulatory Targets for Anticancer Therapeutics
Barta, P. A., Carter, T. R., & Erb, M. A. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00231 · Cited by 2
CDK12-Mediated Phosphorylation of FOXA1 Promotes Prostate Cancer Progression via the MDM2–p53 Axis
Yan, B., Huang, M., Wang, J., Lei, H., Tong, T., Xu, B., Cao, F., Teng, Q., Huang, J., Guan, Y., et al. (2025) · Research · doi:10.34133/research.0990 · Cited by 2
Molecular Pathology of Prostate Cancer
Chen, J., Nelson, W. G., Sfanos, K. S., Yegnasubramanian, S., & Marzo, A. M. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-35118-1_14 · Cited by 2
Androgen receptor-dependent mechanisms mediating therapy resistance in prostate cancer
Saker, Z., Rizk, M., & Nabha, S. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-16032-5.00004-x · Cited by 2
SNP rs9364554 Modulates Androgen Receptor Binding and Drug Response in Prostate Cancer
Yan, Y., Shi, L., Ma, T., Wang, L., & Huang, H. (2025) · Biomolecules · doi:10.3390/biom15010064 · Cited by 2
Lysine methyltransferase SETD7 in cancer: functions, molecular mechanisms and therapeutic implications
Zhang, B., Huang, T., Yang, Y., Li, M., & Shao, G. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10494-3 · Cited by 2
Different FOXA1 classes drive prostate cancer
Stone, L. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0223-1 · Cited by 2
A review on Forkhead Box A1 (FOXA1) gene; A potent candidate for prostate and breast cancer
Awais, M. (2022) · Pure and Applied Biology · doi:10.19045/bspab.2023.120016 · Cited by 2
Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting
Miyahira, A. K., Kamran, S. C., Jamaspishvili, T., Marshall, C. H., Maxwell, K. N., Parolia, A., Zorko, N. A., Pienta, K. J., & Soule, H. R. (2024) · The Prostate · doi:10.1002/pros.24721 · Cited by 2
Self-citation
Phenotypic plasticity and lineage switching in prostate cancer
Somarelli, J. A., Armstrong, A. J., Sheth, M. U., Ware, K. E., & Jolly, M. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817996-3.00021-9 · Cited by 2
BARTweb: a web server for transcription factor association analysisPreprint
Ma, W., Wang, Z., Zhang, Y., Magee, N. E., Chen, Y., & Zang, C. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.17.952838 · Cited by 2
Self-citation
SPOP mutation confers sensitivity to AR-targeted therapy in prostate cancer by reshaping the androgen-driven chromatin landscapePreprint
Grbeša, I., Augello, M. A., Liu, D., McNally, D. R., Gaffney, C., Huang, D., Lin, K., Goueli, R. S., Robinson, B. D., Khani, F., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.20.440154 · Cited by 2
MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancerPreprint
German, B., Singh, J. N., Fonseca, M. A., Burkhart, D. L., Sheahan, A. V., Bergom, H. E., Morel, K. L., Beltran, H., Hwang, J. H., Lawrenson, K., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.31.578216 · Cited by 2
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancerPreprint
Phoenix, J. T., Budreika, A., Schmeck, D. A., Kostlan, R. J., Ferrari, M. G., Young, K. S., Rogers, C. S., Deegan, C. D., Bienko, M. W., Bergom, H. E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.18.664790 · Cited by 2
FoxA1 knockdown promotes BMSC osteogenesis in part by activating the ERK1/2 signaling pathway and preventing ovariectomy-induced bone loss
Li, L., Lin, R., Xu, Y., Li, L., Pan, Z., & Huang, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-88658-1 · Cited by 2
Repurposing alternative splicing events as potential targets for the design of diagnostic and therapeutic tools in PCa
Martínez-Montiel, N., Vite-Arciniega, J. D. J., Rosas-Murrieta, N. H., & Martínez-Contreras, R. D. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1520985 · Cited by 1
The value of MRI-based radiomics and clinicoradiological data for the detection of forkhead box protein A1 gene mutated prostate cancer
Deng, L., Chen, R., Zhou, B., Hu, G., Gan, H., Zhang, L., Zhou, L., Liu, K., & Liu, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-04562-8 · Cited by 1
The Androgen Receptor: Key to Testosterone Function and Androgen Sensitivity
Paakinaho, V., & Palvimo, J. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_12 · Cited by 1
Deep Sequencing Reveals Novel Mutations in Androgen Receptor-Related Genes in Prostate Cancer
Pedroza‐Torres, A., Baranda-Ávila, N., Ramírez, J. L., González, M., González, P. A., Torres, B. L., Jiménez-Ríos, M. Á., Méndez-Tenorio, A., Álvarez-Gómez, R. M., & Hernández, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188758 · Cited by 1
Coactivator networks orchestrating noncanonical AR programs in enzalutamide-resistant CRPC
Gardner, E. J., Ponnusamy, S., & Adelaiye-Ogala, R. M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1748527 · Cited by 1
FOXA1 loss drives basal/squamous de-differentiation of prostate cancer and induces an immunosuppressive tumor microenvironment
Brea, L. T., Shi, H., Keo, V., Huang, J., Peng, L., Chu, Q., Xie, W., Xie, Y., Senthil, S., Breneman, M. T., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71121-8 · Cited by 1
Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer
Moreno-Rodriguez, T., ZHANG, M., Lundberg, A., Shrestha, R., Sjöström, M., Pasam, A., Chan, J., Devereux, L., Foye, A., Zhu, X., et al. (2026) · Genome biology · doi:10.1186/s13059-026-04074-2 · Cited by 1
Self-citation
In silico Study of Clinical Prognosis Associated MicroRNAs for Patients with Metastasis in Clear Cell Renal Carcinoma
Wijaya, E. B., Mekala, V. R., Zaenudin, E., & Ng, K. (2023) · Current Bioinformatics · doi:10.2174/1574893618666230905154441 · Cited by 1
LSD1 inhibitor hinders the demethylation of FOXA1 to inhibit prostate cancer progression
Zhu, Y., Ma, L., Zhang, W. J., & Wu, X. (2023) · Materials Express · doi:10.1166/mex.2023.2567 · Cited by 1
Epigenome editing in cancer: Advances and challenges for potential therapeutic options
Lee, S.-W., Frankston, C. M., & Kim, J. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.10.001 · Cited by 1
The PENGUIN approach to reconstruct protein interactions at enhancer-promoter regions and its application to prostate cancer
Armaos, A., Serra, F., Núñez‐Carpintero, I., Seo, J.-H., Baca, S. C., Gustincich, S., Valencia, A., Freedman, M. L., Cirillo, D., Giambartolomei, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43767-1 · Cited by 1
FOXA1 mutations influence the therapeutic response of breast cancer by altering chromatin state
Arruabarrena-Aristorena, A., & Toska, E. (2021) · Molecular & Cellular Oncology · doi:10.1080/23723556.2021.1891831 · Cited by 1
H3K4me1-marked Enhancer Activation in Resistant Prostate Cancers Implicates SOX4 and MENIN Inhibition as Therapeutic StrategiesPreprint
Terranova, C. J., Maitituoheti, M., Raman, A. T., Tang, M., Anvar, N. E., Ghosh, A. K., Amin, S. B., Schulz, J. E., Orouji, E., Giancotti, F. G., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.02.458625 · Cited by 1
Distinct chromatin scanning modes lead to targeting of compacted chromatin by pioneer factors FOXA1 and SOX2Preprint
Lerner, J., Katznelson, A., Zhang, J., & Zaret, K. S. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.22.521655 · Cited by 1
Rewiring Oncogenic Transcriptional Complexes with Domain-ALTerAtion Chimeras (DALTACs) in Prostate CancerPreprint
Luo, J., Yang, J., Tien, J. C.-Y., Wang, M., Das, S., Wang, X., Young, E., Tošović, J., Mannan, R., Xiang, W., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.24.720638 · Cited by 1
Self-citation
Loss of the Pioneer Factor FOXA1 Results in Genome-wide Epigenetic Reprogramming and activation of Interferon-Response Genes including CD274 /PD-L1Preprint
Hu, W., Yamashita, H., Craig, J. M., Walter, V., Warrick, J. I., Al‐Ahmadie, H. A., & DeGraff, D. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.11.294041
Molekularpathologie und Biomarker
Kirfel, J., & Offermann, A. (2020) · Springer eBooks · doi:10.1007/978-3-662-60643-8_14
Análisis de alteraciones moleculares de SPOP, FOXA1 e IDH1 en cáncer de próstata de población colombiana y sus posibles implicaciones en el pronóstico
Ovalle, M., & Johana, W. (2021)
Genomic characterization of treatment-associated small cell neuroendocrine carcinoma of the prostate
de Kouchkovsky, I., Quigley, D. A., Small, E. J., & Aggarwal, R. R. (2021) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2021.32
Extreme Activation of Androgen Receptor for Prostate Cancer Therapy
Alizadeh‐Ghodsi, M. (2021) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
Decoding androgen receptor inhibitor resistance in prostate cancer
Palit, S. A. L. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1350
BET inhibitor blocks the oncogenic function of nucleophosmin 1 in castration-resistant prostate cancer by interfering with the c-Myc signaling pathwayPreprint
Hong, Z., Xu, C., Wang, X., Jiang, H., Ma, J., Wang, L., Chen, X., Ye, L., & Wu, D. (2022) · Research Square · doi:10.21203/rs.3.rs-1659620/v1
Self-citation
Data from Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors
Stopsack, K. H., Nandakumar, S., Arora, K. S., Nguyen, B., Vasselman, S. E., Nweji, B., McBride, S. M., Morris, M. J., Rathkopf, D. E., Slovin, S. F., et al. (2023) · doi:10.1158/1078-0432.c.6530861
Data from Susceptibility-Associated Genetic Variation in NEDD9 Contributes to Prostate Cancer Initiation and Progression
Han, D. G., Owiredu, J. N., Healy, B. M., Li, M., Labaf, M., Steinfeld, J. S., Patalano, S. C., Gao, S., Liu, M., Macoska, J. A., et al. (2023) · doi:10.1158/0008-5472.c.6513216.v1
Data from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
Hawley, J. R., Zhou, S., Arlidge, C., Grillo, G., Kron, K. J., Hugh-White, R., van der Kwast, T., Fraser, M. E., Boutros, P. C., Bristow, R. G., et al. (2023) · doi:10.1158/0008-5472.c.6513724.v1
Data from Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors
Stopsack, K. H., Nandakumar, S., Arora, K. S., Nguyen, B., Vasselman, S. E., Nweji, B., McBride, S. M. J., Morris, M. J., Rathkopf, D. E., Slovin, S. F., et al. (2023) · doi:10.1158/1078-0432.c.6530861.v1
Supplementary Data from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
Hawley, J. R., Zhou, S., Arlidge, C., Grillo, G., Kron, K. J., Hugh-White, R., van der Kwast, T., Fraser, M. E., Boutros, P. C., Bristow, R. G., et al. (2023) · doi:10.1158/0008-5472.22430878
Supplementary Table 2 from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
Hawley, J. R., Zhou, S., Arlidge, C., Grillo, G., Kron, K. J., Hugh-White, R., van der Kwast, T., Fraser, M. E., Boutros, P. C., Bristow, R. G., et al. (2023) · doi:10.1158/0008-5472.22430854
RETRACTED: New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics
Thakur, N., Quazi, S., Naik, B., Jha, S. K., & Singh, P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1193736
Retracted
Assessing NGS-based computational methods for predicting transcriptional regulators with query gene setsPreprint
Lu, Z., Xiao, X., Zheng, Q., Wang, X., & Xu, L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.01.578316
Self-citation
A Genome Wide CRISPR Screen Reveals That HOXA9 Promotes Enzalutamide Resistance in Prostate Cancer
Roes, M. V., & Dick, F. A. (2024) · Molecular and Cellular Biology · doi:10.1080/10985549.2024.2401465
Experimental Treatment in Prostate Cancer: Gene Profiling and Genetic
van der Poel, H. G. (2025) · Springer eBooks · doi:10.1007/978-3-031-55405-6_8
Pioneer factor FOXA1 can boost CHO cell productivityPreprint
Butterfield, S. P., Saunders, F. L., & White, R. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.10.675314
Genetics‐Driven, Intensity‐Modulated Adaptive Management of Patients With Metastatic Prostate Cancer
Rosales, R. D. R., Venkatesh, A. K., Kanumuambidi, J.-P. T., Ishiyama, Y., Al‐Toubat, M., Sceats, H., Metzner, T. D., Sparks, S., Murray, N. Z., Bandyk, M., et al. (2025) · The Prostate · doi:10.1002/pros.70070
ATHENA: A deep learning–based AI for functional prediction of genomic mutations and synergistic vulnerabilities in prostate cancerPreprint
Cheng, S., Jin, X., Qian, J., Jiang, Y., Kim, I. Y., Deng, S., & Mu, P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.26.690813
Additional file 10 of Systematic interrogation of mutation groupings reveals divergent downstream expression programs within key cancer genes
Grzadkowski, M. R., Holly, H. D., Somers, J., & Demir, E. (2021) · Figshare · doi:10.6084/m9.figshare.14551616
Integrated proteogenomics uncovers ancestry-specific and shared molecular drivers in localized prostate cancerPreprint
Schafer, C. C., Abulez, T. S., Zhang, X., Ho, K.-L., Jiang, J., Young, D., Fox, J., Conrads, K. A., Hood, B. L., Sukumar, G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.28.691220 · Cited by 1
BARTsc identifies key transcriptional regulators from single-cell omics dataPreprint
Zhang, H., Kang, L., Wang, J., Liang, K., Wang, Z., Xu, K., & Zang, C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.24.707729 · Cited by 1
Dissecting FOXA1 pioneering function by acute pharmacological degradationPreprint
Hargis, L. M., Barta, P. A., Zhang, Y., Hayward, R. E., Cravatt, B. F., & Erb, M. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.25.707765
Self-citation
Analysis of Protein–Protein Interactions of Human Pioneer Transcription Factors Based on Predictions of the Structures of Their Complexes
Khasanova, U. N., Gribkova, A. K., Romanova, T. A., Shaytan, A. K., & Алексеевич, А. Г. (2025) · BIOPHYSICS · doi:10.1134/s0006350925700800
Bladder cancer molecular landscapes : multiomics investigations of bladder tumor heterogeneity as biomarkers of treatment response
Groeneveld, C. S. (2023) · theses.fr (ABES) · doi:10.70675/10c68a9dz9fcaz441ez9760zd2be90dbb9d0
The molecular pathology of prostate cancer: an update for practising pathologists
Pereira, F. C., & Marzo, A. M. D. (2026) · Histopathology · doi:10.1111/his.70133
STAG2 loss amplifies EWS-FLI1-driven microsatellite enhancer activity promoting Ewing sarcoma aggressiveness
Eyunni, S., Chu, S., Guan, M. L., Louw, M., YOUNG, E. A., Carson, S. E., Gong, J., Cieslik, M. P., Chinnaiyan, A. M., & Parolia, A. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2537425123 · Cited by 1
Self-citation
Implication de la O-GlcNAcylation dans le trafic intracellulaire : impact de la O-GlcNAc Transférase (OGT) sur le positionnement du système endolysosomal et cartographie de son interactome proximal par BioID
Ahmed, A. B. (2024) · theses.fr (ABES) · doi:10.70675/45334a5dz0e63z46f7zbad2zde4423b66a47
Identification et caractérisation fonctionnelle de la forme cytosolique de la protéine FKBP7 dans le cancer de la prostate chimiorésistant par une approche cellulaire et structurale
Dreno, L. (2024) · theses.fr (ABES) · doi:10.70675/6c1a5fabz24b9z4bf1z8620zcff04e62a34e
Morphological abnormalities in the ureter of type XVII collagen–deficient mice
Suzui, A., Namba, T., Hiraishi, M., Oe, S., Kira, S., Otani, Y., Zhong, R., Natsuga, K., & Ichii, O. (2026) · Scientific Reports · doi:10.1038/s41598-026-49868-3
Connecting multiway enhancer-promoter interactions to changes in gene expression in cancerPreprint
Kumari, K., Shin, S., Shi, G., Reed, K. S. M., Misteli, T., & Thirumalai, D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.25.720760
FOXA1 is a highly sensitive diagnostic marker for prostate cancer including small cell carcinoma of the prostate
Zhao, J., Yao, J., Hosseini, H., Baraban, E. G., Lin, R., Guo, C. C., Huo, L., Lü, W., Khan, K. S., Wang, S., et al. (2026) · Histopathology · doi:10.1111/his.70166
Regulatory Considerations for Biosensor Development for Prostate Cancer
Baghel, N. S., Chaurasia, V., Srivastava, S., & Babu, M. M. H. (2026) · Springer eBooks · doi:10.1007/978-981-95-8644-8_12
3D genome architecture and epigenetic regulation of lineage identity in advanced prostate cancer
Qi, S., & Dehm, S. M. (2026) · Endocrinology · doi:10.1210/endocr/bqag068
Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate CancerPreprint
Rebernick, R. J., Hammer, L., Gondal, M. N., Parolia, A., Wu, Y., Hosseini, N., Schipper, M. J., Kumaraswamy, A., McFarlane, M., Cao, X., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.18.733209
Self-citation
A ligandable PNT domain establishes ERG as a directly targetable oncogenic driver in prostate cancer
Wang, X., Liu, W., Yang, J., Tien, J. C.-Y., Chang, Y., Mannan, R., Mahapatra, S., Zhou, Y., Gan, L., Cao, X., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2537437123
Self-citation
Prostate Cancer Development, Progression, and Therapy
Jin, X., Xiao, Z., Ding, Z., Li, W., Zeng, R., Shuai, Y., Ci, W., Xia, D., Zhang, X., & Huang, H. (2026) · MedComm – Oncology · doi:10.1002/mog2.70082
Multi-omics dissection of FOXA1 reveals cancer-type-specific transcriptional networks and functional risk variants
Luo, B., Zhang, Q., Yang, X., Tan, Z., Qin, L., Yang, Y., Jokela, R., Giannareas, N., Manninen, A., & Wei, G. (2026) · iScience · doi:10.1016/j.isci.2026.117064
Post-translational modifications in prostate cancer: coordinated oncogenic networks and clinical implications
Ren, H., Li, X., Jiang, Z., Bai, Y., & Ai, J. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189692
Mirror worlds: The shared regulatory architecture of cell fate in development and cancer
Fraidenburg, M., Li, L., Kwon, R., Ghali, F., Warrick, J., Leapman, M., Kim, I. Y., & Mu, P. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218799
Targeting the Androgen Receptor and Associated Cofactors in Prostate Cancer: Novel Approaches and Future Perspectives
Dziubańska-Kusibab, P. J., Jourdan, T., & Haendler, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188200
Lineage plasticity as a cellular time machine: reverse developmental logic in cancer evolution
Li, L., Fu, Z., & Mu, P. (2026) · Vita · doi:10.15302/vita.2026.08.0067
The molecular heterogeneity and clinical impact of genomic driver alterations in prostate cancer
Pellegrina, D. V. D. S., Kiriy, D., Cheng, K. C. L., Favero, F., Miletti, E., Klein, Z. P., Hernando, B., Olsen, A. V., Sahli, A., Fu, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-77900-7

Authors: Parolia, A., Cieslik, M., Chu, S.-C., Xiao, L., Ouchi, T., Zhang, Y., Wang, X., Vats, P., Cao, X., Pitchiaya, S., Su, F., Wang, R., Feng, F. Y., Wu, Y.-M., Lonigro, R. J., Robinson, D. R., & Chinnaiyan, A. M.
Affiliations: University of Michigan (US)
Howard Hughes Medical Institute (US)
University of California, San Francisco (US)
Corresponding author: Chinnaiyan, Arul M.
ORCID: Parolia, Abhijit
Cieslik, Marcin
Xiao, Lanbo
Zhang, Yuping
Wang, Xiaoju
Vats, Pankaj
Cao, Xuhong
Pitchiaya, Sethuramasundaram
Su, Fengyun
Wang, Rui
Feng, Felix Y.
Wu, Yi-Mi
Robinson, Dan R.
Chinnaiyan, Arul M.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2019-06-26
Volume: 571
Issue: 7765
Pages: 413-418
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-019-1347-4
PMC: PMC6661908
OpenAlex: W2955719861
Cited by: 284
References: 60
Citations by year: 2026: 25 · 2025: 40 · 2024: 34 · 2023: 44 · 2022: 47 · 2021: 50 · 2020: 35 · 2019: 9
FWCI: 25.92
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Howard Hughes Medical Institute
National Cancer Institute (F99CA245825, R35CA231996, U01CA214170, P50CA186786)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: FOXA1, prostate cancer, activating mutations, androgen receptor, chromatin binding, metastasis, Wnt signaling, TLE3, genome rearrangement, ETS transcription factors, SPOP, carcinogenesis
MeSH terms: Protein Domains, Chromatin, Humans, Male, Models, Molecular, Mutation, Neoplasm Metastasis, Prostatic Neoplasms, Receptors, Androgen, Genome, Human, Gene Expression Regulation, Neoplastic, Cell Line, Tumor, Hepatocyte Nuclear Factor 3-alpha, Wnt Signaling Pathway

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks